Received Mar 23, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 4 | Unknown | PO / MO |
Patient received four doses of Vivotif in consecutive days, instead of every other day; Case reference number US-BN-2024-002380 is a spontaneous case initially received from physician via agency (reference number: USBAV24-2068) on 22-Aug-2024 and concerns a male patient of unknown age. The patient's medical history and concomitant medication details were not provided. On unspecified dates, the patient took four doses of Vivotif (batch number: unknown), four capsules, via oral use for unknown indication. As reported, the patient received Vivotif doses in consecutive days, instead of every other day (explicitly coded as 'inappropriate schedule of vaccine administered'). At the time of the initial report, it was unknown if the patient experienced any adverse events due to Vivotif. Non-significant follow-up was downloaded from VAERS on 09-May-2025 included new reference number. Administrative update performed within the case: Worldwide Unique Case Identification Number (WWID) updated from US-20240822-dd133a to US-BAVARIAN NORDIC A/S-US-BN-2024-002380, in accordance with ICH guidance on WWID formatting.; Reporter's Comments: A male patient of unknown age took four doses of Vivotif for unknown indication. As reported, the patient received Vivotif doses in consecutive days, instead of every other day, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse events due to Vivotif. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A male patient of unknown age took four doses of Vivotif for unknown indication. As reported, the patient received Vivotif doses in consecutive days, instead of every other day, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse events due to Vivotif. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None.